A Study of ZW191 in Participants With Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

October 30, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

January 31, 2027

Conditions
Advanced Solid Tumors
Interventions
DRUG

ZW191

Administered intravenously

Trial Locations (18)

10408

RECRUITING

National Cancer Center, Goyang-si

22031

RECRUITING

NEXT Virginia, Fairfax

43210

RECRUITING

The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus

73104

RECRUITING

Stephenson Cancer Center, Oklahoma City

78229

RECRUITING

NEXT Oncology, San Antonio

119228

RECRUITING

National University Health System (NUHS) - National University Cancer Institute Singapore (NCIS), Singapore

168583

RECRUITING

National Cancer Centre Singapore, Singapore

06510

RECRUITING

Yale University, New Haven

WA 6009

RECRUITING

Linear Clinical Research, Nedlands

NSW 2065

RECRUITING

Royal North Shore Hospital Northern Sydney Cancer Centre, St Leonards

277-8577

RECRUITING

National Cancer Center Hospital East, Kashiwa-shi

350-1298

RECRUITING

Saitama Medical University International Medical Center, Saitama

104-0045

RECRUITING

National Cancer Center Hospital, Tokyo

135-8550

RECRUITING

The Cancer Institute Hospital of JFCR, Tokyo

03080

RECRUITING

Seoul National University Hospital, Seoul

03722

RECRUITING

Severance Hospital, Yonsei University Health System, Seoul

05505

RECRUITING

Asan Medical Center, Seoul

06351

RECRUITING

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Zymeworks BC Inc.

INDUSTRY